| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Jumonji Domain-Containing Histone Demethylases | 4 | 2014 | 43 | 1.280 |
Why?
|
| Myofibroblasts | 2 | 2022 | 23 | 0.890 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 63 | 0.700 |
Why?
|
| Collagen | 2 | 2021 | 156 | 0.670 |
Why?
|
| Cell Culture Techniques | 1 | 2021 | 116 | 0.660 |
Why?
|
| Mutation | 3 | 2021 | 847 | 0.650 |
Why?
|
| Patient Safety | 2 | 2024 | 38 | 0.630 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2018 | 120 | 0.610 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 6 | 2018 | 281 | 0.610 |
Why?
|
| Formative Feedback | 1 | 2018 | 4 | 0.590 |
Why?
|
| Colon | 1 | 2019 | 121 | 0.570 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 459 | 0.570 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 50 | 0.570 |
Why?
|
| Patient Care Team | 1 | 2018 | 67 | 0.560 |
Why?
|
| Quality Improvement | 1 | 2018 | 115 | 0.540 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2017 | 58 | 0.530 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 3 | 2022 | 31 | 0.480 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 121 | 0.480 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 138 | 0.470 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 330 | 0.470 |
Why?
|
| Animals | 22 | 2024 | 10423 | 0.470 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 540 | 0.470 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 405 | 0.460 |
Why?
|
| Cell Proliferation | 8 | 2018 | 806 | 0.450 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2014 | 15 | 0.440 |
Why?
|
| beta Catenin | 1 | 2014 | 66 | 0.420 |
Why?
|
| Humans | 32 | 2024 | 28097 | 0.420 |
Why?
|
| Abiraterone Acetate | 2 | 2024 | 3 | 0.410 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2024 | 13 | 0.400 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 147 | 0.370 |
Why?
|
| Cell Line, Tumor | 11 | 2020 | 1319 | 0.370 |
Why?
|
| Transcription Factors | 1 | 2014 | 520 | 0.330 |
Why?
|
| Mice | 15 | 2023 | 4654 | 0.330 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2021 | 14 | 0.320 |
Why?
|
| Wound Healing | 4 | 2022 | 125 | 0.320 |
Why?
|
| Apoptosis | 7 | 2024 | 775 | 0.320 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2020 | 21 | 0.300 |
Why?
|
| Adipogenesis | 2 | 2020 | 26 | 0.300 |
Why?
|
| Mitochondria | 4 | 2024 | 369 | 0.290 |
Why?
|
| Neoplastic Stem Cells | 3 | 2018 | 141 | 0.270 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2017 | 15 | 0.270 |
Why?
|
| Prednisone | 2 | 2024 | 54 | 0.270 |
Why?
|
| RNA, Small Interfering | 3 | 2018 | 198 | 0.260 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2018 | 77 | 0.250 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2017 | 122 | 0.250 |
Why?
|
| Cells, Cultured | 5 | 2021 | 985 | 0.250 |
Why?
|
| Female | 15 | 2023 | 15156 | 0.250 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 101 | 0.240 |
Why?
|
| Serpins | 2 | 2017 | 31 | 0.240 |
Why?
|
| Wnt Signaling Pathway | 2 | 2017 | 57 | 0.230 |
Why?
|
| DNA Damage | 4 | 2022 | 151 | 0.230 |
Why?
|
| Transcription, Genetic | 4 | 2014 | 403 | 0.230 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2024 | 22 | 0.220 |
Why?
|
| Operating Rooms | 1 | 2024 | 19 | 0.220 |
Why?
|
| Neoplasms | 1 | 2013 | 809 | 0.220 |
Why?
|
| Checklist | 1 | 2024 | 22 | 0.220 |
Why?
|
| Receptors, Immunologic | 1 | 2024 | 72 | 0.210 |
Why?
|
| Phagocytosis | 1 | 2024 | 80 | 0.210 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 2023 | 10 | 0.210 |
Why?
|
| Microglia | 1 | 2024 | 64 | 0.210 |
Why?
|
| Signal Transduction | 7 | 2024 | 1435 | 0.210 |
Why?
|
| Receptors, Estrogen | 1 | 2023 | 43 | 0.210 |
Why?
|
| Pyrimidines | 2 | 2014 | 125 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 144 | 0.210 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 679 | 0.210 |
Why?
|
| Abdominal Wall | 1 | 2023 | 9 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2024 | 409 | 0.200 |
Why?
|
| Membrane Glycoproteins | 1 | 2024 | 145 | 0.200 |
Why?
|
| Rad51 Recombinase | 1 | 2022 | 10 | 0.200 |
Why?
|
| Neoplasm Metastasis | 3 | 2024 | 162 | 0.200 |
Why?
|
| Dermatology | 1 | 2022 | 15 | 0.200 |
Why?
|
| Transcriptome | 2 | 2021 | 214 | 0.190 |
Why?
|
| MicroRNAs | 2 | 2016 | 301 | 0.190 |
Why?
|
| Protein Kinases | 1 | 2022 | 152 | 0.180 |
Why?
|
| Melanoma | 1 | 2022 | 141 | 0.180 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 282 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2018 | 115 | 0.180 |
Why?
|
| Skin Neoplasms | 1 | 2022 | 144 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 1576 | 0.170 |
Why?
|
| Communication | 2 | 2024 | 178 | 0.170 |
Why?
|
| Autophagy | 2 | 2018 | 73 | 0.170 |
Why?
|
| Adipocytes | 2 | 2020 | 56 | 0.170 |
Why?
|
| Intestines | 2 | 2022 | 118 | 0.170 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2022 | 103 | 0.170 |
Why?
|
| Male | 10 | 2024 | 13491 | 0.170 |
Why?
|
| Enzyme Inhibitors | 2 | 2018 | 250 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 2 | 2018 | 315 | 0.160 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 117 | 0.160 |
Why?
|
| Cell Differentiation | 3 | 2022 | 407 | 0.160 |
Why?
|
| Survival Rate | 2 | 2018 | 430 | 0.160 |
Why?
|
| Protein Binding | 4 | 2014 | 658 | 0.160 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 37 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 465 | 0.150 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2018 | 10 | 0.150 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2018 | 8 | 0.150 |
Why?
|
| Retinal Dehydrogenase | 1 | 2018 | 10 | 0.150 |
Why?
|
| Adipose Tissue | 2 | 2017 | 183 | 0.150 |
Why?
|
| Inflammation | 3 | 2023 | 636 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 138 | 0.150 |
Why?
|
| Models, Animal | 1 | 2019 | 129 | 0.150 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2018 | 15 | 0.150 |
Why?
|
| Safety Management | 1 | 2018 | 14 | 0.150 |
Why?
|
| Drug Design | 1 | 2018 | 63 | 0.150 |
Why?
|
| Blotting, Western | 2 | 2017 | 514 | 0.150 |
Why?
|
| Alternative Splicing | 1 | 2018 | 47 | 0.140 |
Why?
|
| Prognosis | 2 | 2018 | 803 | 0.140 |
Why?
|
| Program Development | 1 | 2018 | 78 | 0.140 |
Why?
|
| Health Services Research | 1 | 2018 | 43 | 0.140 |
Why?
|
| Cytokines | 1 | 2020 | 447 | 0.140 |
Why?
|
| Leadership | 1 | 2018 | 53 | 0.140 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 66 | 0.140 |
Why?
|
| Growth Disorders | 1 | 2017 | 21 | 0.140 |
Why?
|
| Homeostasis | 2 | 2018 | 118 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 453 | 0.140 |
Why?
|
| STAT1 Transcription Factor | 1 | 2017 | 38 | 0.140 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2017 | 39 | 0.140 |
Why?
|
| Macrophages | 1 | 2020 | 295 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2018 | 167 | 0.140 |
Why?
|
| Microtubules | 2 | 2017 | 90 | 0.140 |
Why?
|
| Rats | 1 | 2021 | 1576 | 0.140 |
Why?
|
| Antigens, CD19 | 1 | 2017 | 13 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2018 | 125 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 67 | 0.140 |
Why?
|
| Mice, SCID | 1 | 2017 | 61 | 0.130 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 49 | 0.130 |
Why?
|
| Lymphopoiesis | 1 | 2017 | 22 | 0.130 |
Why?
|
| RNA Interference | 2 | 2015 | 137 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2017 | 74 | 0.130 |
Why?
|
| HT29 Cells | 2 | 2014 | 20 | 0.130 |
Why?
|
| Organogenesis | 1 | 2017 | 12 | 0.130 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2016 | 5 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 32 | 0.130 |
Why?
|
| Wnt Proteins | 1 | 2017 | 34 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 118 | 0.130 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 15 | 0.130 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2017 | 34 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 167 | 0.130 |
Why?
|
| Qualitative Research | 1 | 2018 | 192 | 0.130 |
Why?
|
| Stromal Cells | 1 | 2017 | 61 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 36 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2016 | 52 | 0.130 |
Why?
|
| Oxidative Stress | 2 | 2017 | 668 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 2 | 2015 | 343 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 40 | 0.120 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 478 | 0.120 |
Why?
|
| Focal Adhesions | 1 | 2015 | 15 | 0.120 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 283 | 0.120 |
Why?
|
| Magnaporthe | 1 | 2014 | 5 | 0.110 |
Why?
|
| Guanosine Triphosphate | 1 | 2014 | 29 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2014 | 3 | 0.110 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2014 | 25 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 109 | 0.110 |
Why?
|
| Eye Injuries | 1 | 2014 | 11 | 0.110 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2014 | 30 | 0.110 |
Why?
|
| Epithelium, Corneal | 1 | 2014 | 14 | 0.110 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2014 | 6 | 0.110 |
Why?
|
| Benzodiazepinones | 1 | 2014 | 13 | 0.110 |
Why?
|
| Endosomes | 1 | 2014 | 45 | 0.110 |
Why?
|
| Cell Movement | 4 | 2018 | 373 | 0.110 |
Why?
|
| Gene Expression | 2 | 2014 | 417 | 0.110 |
Why?
|
| Transcription Factor 4 | 1 | 2014 | 5 | 0.110 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2014 | 12 | 0.110 |
Why?
|
| Docosahexaenoic Acids | 1 | 2015 | 105 | 0.110 |
Why?
|
| ErbB Receptors | 1 | 2014 | 100 | 0.110 |
Why?
|
| Fungal Proteins | 1 | 2014 | 82 | 0.110 |
Why?
|
| Cyclin D1 | 1 | 2014 | 38 | 0.110 |
Why?
|
| Pyrazoles | 1 | 2014 | 66 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2013 | 22 | 0.110 |
Why?
|
| Transcriptional Activation | 1 | 2014 | 86 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 44 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 165 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 48 | 0.110 |
Why?
|
| Exosomes | 1 | 2015 | 96 | 0.110 |
Why?
|
| Virus Replication | 1 | 2013 | 65 | 0.110 |
Why?
|
| Hepacivirus | 1 | 2013 | 48 | 0.110 |
Why?
|
| Transcription Factor 3 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 156 | 0.100 |
Why?
|
| Indoles | 1 | 2013 | 99 | 0.100 |
Why?
|
| Osteoclasts | 1 | 2012 | 29 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 27 | 0.100 |
Why?
|
| United States | 1 | 2018 | 2146 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 632 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 490 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2017 | 507 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 356 | 0.080 |
Why?
|
| Fibrosis | 2 | 2022 | 133 | 0.080 |
Why?
|
| Fibroblasts | 2 | 2022 | 157 | 0.080 |
Why?
|
| Cell Survival | 3 | 2016 | 409 | 0.080 |
Why?
|
| Chickens | 2 | 2018 | 61 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2020 | 288 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 769 | 0.070 |
Why?
|
| HEK293 Cells | 2 | 2018 | 187 | 0.070 |
Why?
|
| Mitochondrial Dynamics | 2 | 2017 | 12 | 0.070 |
Why?
|
| Phenotype | 2 | 2020 | 681 | 0.070 |
Why?
|
| Biological Transport | 2 | 2017 | 122 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2018 | 331 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 103 | 0.060 |
Why?
|
| Bone and Bones | 2 | 2017 | 75 | 0.060 |
Why?
|
| Skin | 2 | 2017 | 149 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2021 | 2546 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 578 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2017 | 848 | 0.050 |
Why?
|
| Lysosomes | 1 | 2024 | 56 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 49 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 134 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 56 | 0.050 |
Why?
|
| Tissue Adhesions | 1 | 2023 | 4 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 176 | 0.050 |
Why?
|
| Weight Gain | 1 | 2023 | 75 | 0.050 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2022 | 20 | 0.050 |
Why?
|
| Recombinational DNA Repair | 1 | 2022 | 7 | 0.050 |
Why?
|
| Middle Aged | 3 | 2024 | 7138 | 0.050 |
Why?
|
| Estradiol | 1 | 2023 | 175 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2022 | 14 | 0.050 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2022 | 26 | 0.050 |
Why?
|
| Permeability | 1 | 2022 | 61 | 0.050 |
Why?
|
| Hydrogels | 1 | 2023 | 58 | 0.050 |
Why?
|
| DNA Repair | 1 | 2022 | 82 | 0.050 |
Why?
|
| Cell Line | 1 | 2024 | 696 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 53 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2024 | 887 | 0.050 |
Why?
|
| Proteomics | 1 | 2023 | 181 | 0.050 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 220 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 94 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2022 | 157 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 53 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2022 | 197 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 237 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2020 | 20 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 90 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 38 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 521 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 1461 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 172 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 2021 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2022 | 885 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 178 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 16 | 0.040 |
Why?
|
| Ubiquitin | 1 | 2018 | 24 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2018 | 29 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 208 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2020 | 226 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2018 | 243 | 0.040 |
Why?
|
| Atrophy | 1 | 2017 | 15 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2017 | 25 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2017 | 27 | 0.040 |
Why?
|
| Obesity | 1 | 2023 | 669 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2017 | 25 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2017 | 44 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 1248 | 0.030 |
Why?
|
| Kinetics | 1 | 2018 | 545 | 0.030 |
Why?
|
| Protein Domains | 1 | 2017 | 52 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 58 | 0.030 |
Why?
|
| Interferons | 1 | 2017 | 69 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 269 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 452 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2017 | 77 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 607 | 0.030 |
Why?
|
| Lipodystrophy | 1 | 2017 | 6 | 0.030 |
Why?
|
| Sulfoxides | 1 | 2016 | 6 | 0.030 |
Why?
|
| Dynamins | 1 | 2016 | 7 | 0.030 |
Why?
|
| Enterocytes | 1 | 2016 | 14 | 0.030 |
Why?
|
| Isothiocyanates | 1 | 2016 | 11 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2017 | 29 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 44 | 0.030 |
Why?
|
| Point Mutation | 1 | 2017 | 60 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2017 | 51 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 103 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2016 | 40 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2016 | 42 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 31 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2016 | 68 | 0.030 |
Why?
|
| Aorta | 1 | 2017 | 124 | 0.030 |
Why?
|
| Integrases | 1 | 2016 | 39 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2017 | 140 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 180 | 0.030 |
Why?
|
| Stem Cells | 1 | 2016 | 121 | 0.030 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2016 | 98 | 0.030 |
Why?
|
| rab27 GTP-Binding Proteins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 1013 | 0.030 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2015 | 33 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2016 | 248 | 0.030 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2014 | 3 | 0.030 |
Why?
|
| Antioxidants | 1 | 2016 | 223 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2021 | 2379 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 60 | 0.030 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2014 | 6 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 133 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 2014 | 34 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2015 | 124 | 0.030 |
Why?
|
| Plant Diseases | 1 | 2014 | 39 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2014 | 32 | 0.030 |
Why?
|
| Laminin | 1 | 2014 | 21 | 0.030 |
Why?
|
| Aged | 1 | 2024 | 5400 | 0.030 |
Why?
|
| Oryza | 1 | 2014 | 40 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 179 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 38 | 0.030 |
Why?
|
| Lentivirus | 1 | 2014 | 16 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 50 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2014 | 119 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 328 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2014 | 51 | 0.030 |
Why?
|
| Lithium | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hair Follicle | 1 | 2014 | 9 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2014 | 86 | 0.030 |
Why?
|
| Endocytosis | 1 | 2014 | 89 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2014 | 71 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2014 | 48 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2014 | 42 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2014 | 77 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 124 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 30 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2014 | 87 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 257 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2014 | 116 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 276 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2015 | 152 | 0.030 |
Why?
|
| Microcirculation | 1 | 2014 | 112 | 0.030 |
Why?
|
| Binding Sites | 1 | 2014 | 353 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 199 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 765 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2013 | 80 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 10 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2012 | 14 | 0.030 |
Why?
|
| RANK Ligand | 1 | 2012 | 19 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 2012 | 11 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 692 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 149 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2012 | 23 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2013 | 112 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 1191 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 131 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 473 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 29 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2015 | 352 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 147 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2014 | 337 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 161 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 289 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 586 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 331 | 0.020 |
Why?
|
| Adult | 1 | 2014 | 7740 | 0.010 |
Why?
|